Pharmacogenomics Technologies Patent Landscape Analysis Report 2026 Edition

Pharmacogenomics Technologies Market Size, Growth Trends, and Industry Outlook

Pharmacogenomics technologies match a patient's inherited variants in drug-metabolising enzymes, transporters, receptors and immune genes to the choice and dose of a medicine. Demand comes from psychiatry, oncology, cardiology, pain management and transplant care, where trial-and-error prescribing carries clinical and cost penalties. Laboratories, hospital systems and pharmacies adopt these tools to cut adverse drug reactions and shorten the time to an effective regimen. Technology supply runs from low-cost genotyping assays to whole-genome sequencing and interpretation software.

Market growth is driven by drug labels and guidelines that name actionable genes, which turn genotyping into a routine step before prescribing. Adverse drug reactions account for about 6.5% of hospital admissions in a large United Kingdom study, which gives payers a reason to fund prevention. The 2023 PREPARE trial (6,944 patients, seven European countries) found 30% fewer clinically relevant reactions with genotype-guided prescribing.

The February 2026 boxed warning on capecitabine and fluorouracil, with its advice to test for DPYD variants first, widens the volume of oncology tests that laboratories run. A federal court vacated the FDA rule on laboratory-developed tests in March 2025, which keeps the in-house panel route open. Reimbursement is uneven: after UnitedHealthcare ended multi-gene panel coverage in early 2025, Myriad Genetics reported GeneSight revenue down 17% for nine months while test volume rose 5%. Volume growth alongside price pressure holds the growth rate at a moderate double-digit level.

Read more about this report - Request a Free Sample

Pharmacogenomics Technologies Patent Filing Trends and Innovation Activity

Patent filings in pharmacogenomics technologies concentrate on assay chemistry, array and panel design, variant calling and clinical interpretation. Allele-specific PCR and array claims for CYP2C19, CYP2D6, CYP2C9, VKORC1, DPYD and HLA alleles form the oldest cluster, while sequencing and software claims make up the fastest growing one.

The report tracks more than 12,500 patent families, with filings peaking in 2007 and 2008 during the first wave of microarray-based tests and rising again from 2019 as sequencing, structural-variant resolution of CYP2D6 and decision support software matured. Applicants file first in the United States and extend to Europe, China, Japan and South Korea.

Regulatory labelling and payer scrutiny push assignees to protect interpretation logic and workflow integration, since assay chemistry for common variants has become widely available.

Scope of the Pharmacogenomics Technologies Patent Landscape Analysis Report

The report covers patents on genotyping arrays and multiplex PCR assays for pharmacogenes, mass spectrometry genotyping, targeted and whole-genome sequencing panels, long-read resolution of complex loci, and star allele and diplotype calling software.

Clinical decision support tools, pre-emptive testing workflows and pharmacy-based sample collection are included where claims link to genotype-guided prescribing. Patents on tumour somatic profiling and companion diagnostics for single drugs appear only where claims address germline drug-response variants.

Assignees assessed include diagnostic and instrument manufacturers, clinical laboratories, health systems, universities and software developers, with subsidiaries consolidated under their parent companies.

Global Pharmacogenomics Technologies Patent Landscape Analysis

Pharmacogenomics Technologies Patent Filing Trend Analysis

Annual filings in pharmacogenomics technologies grew at an estimated 7 to 9% per year over 2020-2024. Sequencing-based calling of hard-to-type genes such as CYP2D6 and the move of laboratories to multi-gene panels drove most of this increase.

Grants in 2025 reached roughly 1,150 patents, with a rising share covering software, interpretation algorithms and data integration. Array and PCR chemistry claims, many filed in the 2000s, are expiring, which opens room for lower-cost assay developers.

Leading Companies and Assignee Analysis in the Pharmacogenomics Technologies Patent Landscape

Geographic Analysis of Pharmacogenomics Technologies Patent Activity

The report assesses patent activity across major jurisdictions, including:

• United States
• Europe
• China
• Japan
• South Korea
• India
• International and WIPO filings

The United States leads filing volume, supported by a large clinical laboratory sector and early guideline development by CPIC. China ranks second as domestic instrument makers and hospital genetics centres scale up genotyping for carbamazepine, clopidogrel and fluoropyrimidine safety. Europe follows, with filings tied to DPYD testing policy, the PREPARE programme and Dutch Pharmacogenetics Working Group guidance.

Read more about this report - Request a Free Sample

Pharmacogenomics Technologies Technology Segmentation and Innovation Areas

Patent activity is organised across the following technology segments:

• Genotyping arrays and multiplex PCR assays for pharmacogenes
• Mass spectrometry and allele-specific amplification methods
• Targeted, whole-genome and long-read sequencing panels
• Star allele calling and diplotype interpretation software
• Clinical decision support and pre-emptive testing workflows

Among these, genotyping arrays and PCR assays hold the largest share of patent families because of their long filing history, while sequencing and software segments record the fastest growth.

Competitive Landscape and Emerging Trends in the Pharmacogenomics Technologies Market

Competition in pharmacogenomics technologies spans instrument suppliers, assay developers and clinical laboratories. Roche, Illumina and Thermo Fisher Scientific hold broad platform claims, Myriad Genetics protects psychiatric decision-support methods tied to GeneSight, and Qiagen covers PCR-based kits for European laboratories. Specialist developers of star allele callers and clinical decision support compete on interpretation accuracy.

Companies are focusing on:

• Multiplexed genotyping arrays covering core pharmacogenes
• Long-read and targeted sequencing of CYP2D6 structural variants
• Star allele calling and diplotype algorithms
• DPYD, TPMT and NUDT15 toxicity testing for chemotherapy
• HLA allele typing for hypersensitivity prevention
• Pre-emptive panel testing integrated with electronic health records
• Pharmacy-based collection and point-of-dispensing workflows

Emerging innovation themes include long-read sequencing for complex loci, machine learning models that predict drug response from combined genotype and clinical data, polygenic scores for treatment outcome, and pharmacogenomic alerts delivered inside prescribing systems. Population-specific allele panels for South Asian, East Asian and African ancestry groups are also gaining filings.

Strategic Insights from the Pharmacogenomics Technologies Patent Landscape

Assignees with sequencing and array platforms hold a structural advantage because they supply the instruments behind many laboratory-developed panels. Opportunities for newer entrants sit in interpretation software, ancestry-aware allele coverage and low-cost point-of-care genotyping, where claim density is lower. Licensing and partnership activity between laboratories and software developers is likely to increase as panels move into routine care.

Technology segments, assignee portfolios and jurisdiction trends are assessed to show where claims are dense and where gaps remain. The report provides actionable intelligence supporting:

• Intellectual property strategy
• R&D prioritisation
• Competitive benchmarking
• Technology scouting
• Licensing evaluation
• Partnership assessment
• Investment analysis
• Market entry planning
• Portfolio expansion strategy

Research Methodology for the Pharmacogenomics Technologies Patent Landscape Analysis

The analysis draws on patent records from the United States Patent and Trademark Office, the European Patent Office, the China National Intellectual Property Administration, the Japan Patent Office, the Korean Intellectual Property Office and WIPO PATENTSCOPE. Records are searched by publication date through 2025.

Queries combine CPC classes C12Q 1/6883 and C12Q 1/6869, IPC class G16B 20/00 and G16H 20/10, with keywords for pharmacogene names, star alleles and drug-gene pairs. Results are screened manually, deduplicated and consolidated into patent families, with assignee names harmonised to parent companies.

The market side draws on regulatory labelling and clearances, company filings, clinical trial registries, CPIC and Dutch Pharmacogenetics Working Group guidelines, and peer-reviewed literature. Patent counts are rounded approximations.

Related Reports

Genomics Market

Personalized Medicine Market

Companion Diagnostics Patent Landscape Analysis Report